Post-PET Management Pathway Category Details (n = 242)
| Potential management before PSMA PET | Potential management after PSMA PET | Change category | n |
|---|---|---|---|
| Active surveillance | Active surveillance | No change | 2 (1%) |
| Local RT (prostatic bed) | Local RT | No change | 46 (19%) |
| +SIB | Minor | 39 (16%) | |
| +SIB, +ADT | Major | 9 (5%) | |
| +ADT | Minor | 2 (1%) | |
| Surgery | Major | 5 (2%) | |
| SBRT ± SIB | Major | 7 (3%) | |
| HCTx | Major | 1 (0%) | |
| Active surveillance | Major | 3 (1%) | |
| Local RT + ADT | Local RT + ADT | No change | 16 (7%) |
| +SIB | Minor | 59 (24%) | |
| Only local RT | Minor | 1 (0%) | |
| Only ADT | Major | 1 (0%) | |
| +SIB, +RTx field enlargement | Major | 1 (0%) | |
| SBRT | Major | 3 (1%) | |
| +SIB, +SBRT | Major | 3 (1%) | |
| Surgery | Major | 10 (4%) | |
| ADT + SGARI | Major | 7 (3%) | |
| HCTx | Major | 2 (1%) | |
| No therapy without prior imaging possible | HCTx | NA | 7 (3%) |
| ADT + SGARI | NA | 3 (1%) | |
| SBRT | NA | 1 (0%) | |
| Local RT ± ADT ± SIB ± SBRT | NA | 12 (5%) | |
| Surgery | NA | 2 (1%) |
RT = radiation therapy; SIB = simultaneous integrated boost; SBRT = stereotactic body radiotherapy; HCTx = hormone chemotherapy; NA = not applicable; SGARI = second-generation androgen receptor inhibitor.